- Sustainability and responsible business risks and opportunities extend beyond our immediate operations as they are also manifested in our partners’ businesses.
- Scope 3 emissions related to portfolio investments are the most material emissions category.
Royalty Pharma plc
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Royalty Pharma plc disclosed greenhouse gas emissions of 32.0K tCO2e/year. By scope: Scope 3: 32.0K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
32.0K tCO2e/year
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 32.0K tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 32.0K tCO2e/year |
| 2022 | 19.6K tCO2e/year (Scope 3 Category 15) |
| 2021 | 315.7K tCO2e (Scope 3 Category 15) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Provided online training on sustainability and recycling efforts and procedures.
- New York City office is Energy Star certified and WELL designated.
🌱 ESG Focus Areas
Responsible InvestmentAccess to Health and MedicineDiversity, Equity and InclusionHuman Capital ManagementCorporate Governance